Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva (NYSE:TEVA) announced FDA approval of PONLIMSI (denosumab-adet) for all Prolia indications and acceptance of BLA/MAA filings for a proposed omalizumab biosimilar in the U.S. and EU. The EMA granted marketing authorization for PONLIMSI in November 2025, and FDA approval occurred on March 30, 2026.
Teva positions these regulatory milestones as part of its Pivot to Growth strategy to expand its global biosimilars portfolio and commercialization capabilities.
Teva (NYSE: TEVA) posted its Q1 2026 Aide Memoire to the Investors page to help investors ahead of first-quarter results. The document compiles previously disclosed public information, management commentary and select independent data.
Teva expects to release Q1 2026 results on April 29, 2026 at 7:00 AM ET, with a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) will release its first quarter 2026 financial results on April 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day. Registration is required for phone participation and a replay will be available within 24 hours on Teva's investor website.
Teva (NYSE: TEVA) and Blackstone Life Sciences announced a $400 million strategic funding agreement over four years to support development of duvakitug, a human monoclonal antibody targeting TL1A in phase 3 studies for ulcerative colitis and Crohn’s disease.
BXLS may earn regulatory and commercial milestones plus low single-digit royalties on worldwide sales, and Teva remains co-developer/co-commercializer with Sanofi subject to regulatory approval.
Teva (NYSE: TEVA) announced that President and CEO Richard Francis will participate in three investor conferences in March 2026: UBS European Healthcare Conference (Mar 3, investor meetings only), Leerink Partners Global Healthcare Conference (Mar 9, 10:00 AM ET, webcast fireside chat), and Barclays 28th Annual Global Healthcare Conference (Mar 10, 8:00 AM ET, webcast fireside chat).
Live webcasts and archived recordings (available within 24 hours, accessible for up to 30 days) will be hosted on Teva's Investor Relations website.
Teva (NYSE: TEVA) announced FDA acceptance of its New Drug Application for TEV-'749, an investigational once-monthly subcutaneous olanzapine extended-release injectable suspension on Feb 20, 2026.
The NDA is supported by Phase 3 SOLARIS Week 56 results showing efficacy and safety consistent with existing olanzapine formulations and no evidence requiring post-injection monitoring; TEV-'749 uses Medincell's SteadyTeq sustained-release copolymer technology.
Teva (NYSE:TEVA) and Sanofi reported positive RELIEVE UCCD LTE phase 2b results for investigational duvakitug, showing durable clinical and endoscopic efficacy maintained for 44 weeks in patients with ulcerative colitis and Crohn’s disease who responded to induction.
At week 44, clinical remission in UC was 58% (900 mg) and 47% (450 mg); endoscopic response in CD was 55% (900 mg) and 41% (450 mg). Safety was consistent with induction; detailed results will be presented at a medical meeting. Teva will host an investor call and webcast on Feb 17, 2026.
Teva (NYSE:TEVA) reported 2025 revenues of $17.3 billion, a 4% YoY increase (3% in local currency), marking its third consecutive year of growth. Key innovative brands surpassed $3 billion (+35% YoY LC), with AUSTEDO $2.26B and AJOVY $673M. Gross profit rose 11% to $8.94B. Free cash flow was $2.40B, debt reduced via $1.812B senior note repayment, and 2026 guidance forecasts revenues of $16.4–$16.8B and non-GAAP diluted EPS of $2.57–$2.77.
Teva (NYSE:TEVA) on Jan 27, 2026 announced a partnership with actor and advocate Will Forte to raise awareness of Huntington’s disease (HD) through the Honestly HD program.
The campaign highlights HD symptoms including chorea—involuntary movements affecting up to 90% of people with HD—and directs people to educational resources at HonestlyHD.com. The release notes HD affects more than 41,000 people in the U.S.
Teva (NYSE: TEVA) announced publication in the New England Journal of Medicine of Phase 3 SPACE trial results showing AJOVY (fremanezumab-vfrm) significantly reduced monthly migraine days and monthly headache days versus placebo in children and adolescents with episodic migraine.
Key results: MMD reduction 2.5 days with AJOVY vs 1.4 days placebo (difference 1.1 days; P=0.02); MHD reduction 2.6 vs 1.5 days (difference 1.1 days; P=0.02); ≥50% MMD responder rate 47.2% vs 27.0% (P=0.002). The 3-month trial enrolled 237 patients. The data supported FDA approval in August 2025 for preventive treatment of episodic migraine in patients aged 6–17 years weighing ≥45 kg. No new safety signals identified.